Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer: a Multicentre, Multicohort, Phase 2 Trial.

NCT07714447 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07714447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07714447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer: a Multicentre, Multicohort, Phase 2 Trial.
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
February 26, 2029
Enrollment
91 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf, crc (colorectal cancer)